Suppr超能文献

经尿道钬激光前列腺剜除术后当日导尿管拔除失败的预测因素。

Predictors of Failed Same-Day Catheter Removal After Holmium Laser Enucleation of the Prostate.

机构信息

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.

出版信息

Urology. 2022 Dec;170:168-173. doi: 10.1016/j.urology.2022.07.047. Epub 2022 Aug 10.

Abstract

OBJECTIVE

To determine factors associated with failure of same-day trial of void (SDTOV) following holmium laser enucleation of the prostate (HoLEP).

BACKGROUND

HoLEP is increasingly utilized for patients with benign prostatic hyperplasia. Advancements in technology have improved operative efficiency and hemostasis making same-day, catheter-free discharge possible.

METHODS

We conducted a retrospective review on 190 patients undergoing HoLEP from July, 2021 to January, 2022 by a single center. We assessed pre- and intra-operative variables associated with our primary outcome: failure of same-day catheter removal. Post-operative complications and outcomes at a ≤7 days and 3-month follow up were examined. Continuous and categorical variables were analyzed using unpaired t-tests (Mann Whitney) and chi-square, respectively. Univariate and multivariable logistic regression models were fitted to examine the associations of failed SDTOV.

RESULTS

Of 190 candidates for a SDTOV, 90% (171/190) were successful. We found no difference between SDTOV success and failures with regards to age, comorbidities, presence of pre-operative urinary retention, anesthesia factors, operative time, volume resected, enucleation time, and morcellation time (all P>0.05). Pre-operatively, 26.3% (50/190) were on antiplatelet and 6.3% (12/190) were on anticoagulation. While pre-operative antiplatelet therapy was not associated with SDTOV failure (P=0.78), pre-operative anticoagulation use was (4.7% vs. 21.1%, P=0.021). Patients who continued anticoagulation through surgery had the highest rate of SDTOV failure (2.3% (4/171) vs. 15.8% (3/19), P=0.023). For those with successful SDTOV, 4.1% (7/171) required catheterization following discharge. At 3 months, no patient required catheterization.

CONCLUSION

On the day of surgery, patients eligible for SDTOV successfully voided 90% of the time. History of preop anticoagulation, whether continued or held, increased SDTOV failure.

摘要

目的

确定与钬激光前列腺剜除术(HoLEP)后即刻试排空失败(SDTOV)相关的因素。

背景

HoLEP 越来越多地用于治疗良性前列腺增生症患者。技术的进步提高了手术效率和止血效果,使患者能够在同一天、无导管的情况下出院。

方法

我们对 2021 年 7 月至 2022 年 1 月期间由单中心进行的 190 例 HoLEP 患者进行了回顾性研究。我们评估了与主要结局(即同日导管拔除失败)相关的术前和术中变量。检查了术后 ≤7 天和 3 个月随访时的并发症和结果。连续和分类变量分别采用未配对 t 检验(Mann Whitney)和卡方检验进行分析。采用单变量和多变量逻辑回归模型来检验 SDTOV 失败的相关性。

结果

在 190 名符合 SDTOV 条件的患者中,90%(171/190)成功。我们发现,在 SDTOV 成功与失败方面,年龄、合并症、术前尿潴留、麻醉因素、手术时间、切除体积、剜除时间和切碎时间等方面均无差异(所有 P>0.05)。术前,26.3%(50/190)患者正在服用抗血小板药物,6.3%(12/190)患者正在服用抗凝药物。虽然术前抗血小板治疗与 SDTOV 失败无关(P=0.78),但术前抗凝治疗与 SDTOV 失败相关(4.7%比 21.1%,P=0.021)。在手术期间继续抗凝治疗的患者 SDTOV 失败率最高(2.3%[4/171]比 15.8%[3/19],P=0.023)。对于成功进行 SDTOV 的患者,4.1%(7/171)在出院后需要再次置管。在 3 个月时,没有患者需要置管。

结论

在手术当天,有资格进行 SDTOV 的患者 90%的时间能够成功排空。术前抗凝治疗的病史,无论是否继续或停止,都会增加 SDTOV 失败的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验